奥希替尼靶向治疗对晚期非小细胞肺癌患者的效果及有效率评价  

Evaluation of the Efficacy and Efficacy of Osimertinib Targeted Therapy in Patients with Advanced Non-small Cell Lung Cancer

作　　者：鲁雷 李家信 王兰 LU Lei;LI Jiaxin;WANG Lan(Department of Oncology,Guizhou Provincial Staff Hospital,Guiyang 550025,Guizhou,China)

机构地区：[1]贵州省职工医院肿瘤科,贵州贵阳550025

出　　处：《系统医学》2025年第7期171-174,共4页Systems Medicine

摘　　要：目的 探讨奥希替尼靶向治疗晚期非小细胞肺癌的临床效果及有效率。方法 随机选取2021年1月—2022年1月贵州省职工医院肿瘤科收治的100例晚期非小细胞肺癌患者为研究对象,按治疗方法不同分为对照组和观察组,每组50例,对照组予以常规化疗方案,观察组联合奥希替尼靶向治疗。对比两组肿瘤标志物水平、免疫功能指标、临床疗效以及不良反应、预后情况。结果 治疗后,观察组糖类抗原125、癌胚抗原、细胞角蛋白21片段抗原水平均低于对照组,观察组CD3+、CD4+以及CD4+/CD8+水平均高于对照组,差异均有统计学意义(P均<0.05);观察组治疗总有效率74.00%(37/50)高于对照组46.00%(23/50),差异有统计学意义(χ^(2)=8.167,P<0.05);两组均出现恶心呕吐、腹泻、贫血、白细胞减少情况,且两组不良反应发生情况比较,差异均无统计学意义(P均>0.05)。观察组6个月无进展率、总生存率高于对照组,无进展生存期、总生存期长于对照组,差异均有统计学意义(P均<0.05)。结论 晚期非小细胞肺癌在常规化疗基础上,联合奥希替尼靶向治疗效果较佳。Objective To investigate the clinical effect and efficiency of osimertinib in the treatment of advanced non-small cell lung cancer.Methods A total of 100 patients with advanced non-small cell lung cancer admitted to the De⁃partment of Oncology,Guizhou Provincial Staff Hospital from January 2021 to January 2022 were randomly selected as the study subjects.According to different treatment methods,they were divided into control group and observation group,with 50 cases in each group.The control group was given conventional chemotherapy,and the observation group was combined with osimertinib targeted therapy.The levels of tumor markers,immune function indexes,clinical efficacy,adverse reactions and prognosis were compared between the two groups.Results After treatment,the levels of carbohydrate antigen 125,carcinoembryonic antigen and cytokeratin fragment 21-1 in the observation group were lower than those in the control group,and the levels of CD3+,CD4+and CD4+/CD8+in the observation group were higher than those in the control group,with statistically significant differences(all P<0.05).The total effective rate of the observation group was 74.00%(37/50),which was higher than 46.00%(23/50)of the control group,and the differ⁃ence was statistically significant(χ^(2)=8.167,P<0.05).Nausea and vomiting,diarrhea,anemia and leukopenia occurred in both groups,and there were no significant differences in the incidence of adverse reactions between the two groups(all P>0.05).The 6-month progression-free rate and overall survival rate of the observation group were higher than those of the control group,and the progression-free survival and overall survival were longer than those of the control group,the differences were statistically significant(all P<0.05).Conclusion The combination of conventional chemo⁃therapy and ositinib targeted therapy is more effective for advanced non-small cell lung cancer.

关 键 词：晚期非小细胞肺癌 奥希替尼 靶向治疗 临床效果 

分 类 号：R734[医药卫生—肿瘤]